Tilray (NASDAQ:TLRY - Get Free Report) posted its earnings results on Thursday. The company reported ($0.01) earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.03, Briefing.com reports. Tilray had a negative net margin of 30.26% and a negative return on equity of 2.63%. The company had revenue of $200.00 million during the quarter, compared to analyst estimates of $218.70 million. During the same period in the prior year, the business posted ($0.10) earnings per share. Tilray's revenue for the quarter was up 13.0% on a year-over-year basis.
NASDAQ TLRY opened at $1.63 on Thursday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.42 and a current ratio of 2.27. Tilray has a fifty-two week low of $1.50 and a fifty-two week high of $2.97. The stock has a market cap of $1.26 billion, a P/E ratio of -3.70 and a beta of 2.13. The stock has a 50 day simple moving average of $1.77 and a two-hundred day simple moving average of $1.86.
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Tilray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.
While Tilray currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.